Wednesday, June 22, 2011
Unknown
An international team of scientists has developed a new drug for cystic fibrosis sufferers.
VX-770 targets people with the 'celtic gene', a genetic mutation particularly common in patients with the condition.
VX-770 works by opening the defective channel in lungs cells of people with cystic fibrosis. It is the first treatment aimed at this basic defect to show an effect.
Posted in: Pharma news
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.